U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. FDA Organization
  4. Office of the Commissioner
  5. Office of the Chief Scientist
  6. National Center for Toxicological Research
  7. Science & Research (NCTR)
  8. Yiying Wang
  1. Science & Research (NCTR)

Yiying Wang Ph.D.
Leadership Role

Staff Fellow — Division of Genetic and Molecular Toxicology

No photo available


Yiying Wang, Ph.D.
(870) 543-7121
NCTRResearch@fda.hhs.gov  

Back to NCTR Principal Investigators page

About  |  Publications  |  Lab Members

Background

Dr. Yiying Wang received a Ph.D. in physiology and biophysics from the University of Arkansas for Medical Sciences (UAMS) in 2008. She then joined NCTR as an ORISE Postdoctoral Fellow, training with Dr. Barbara Parsons, where she conducted research on the mutagenic mode of action of carcinogens that mediate tissue-specific carcinogenesis and on the potential of using oncomutations as a biomarker for cancer risk assessment and personalized therapy. Between 2012 and 2013, she received additional postdoctoral training at UAMS, participating in National Institute of Health (NIH)-funded research to investigate the impact of autophagy inhibition as a potential therapeutic approach for the treatment of age-associated bone mass loss. In 2016, Dr. Wang rejoined NCTR as an FDA staff fellow in the Division of Genetic and Molecular Toxicology (DGMT). During her research career, she has published 24 articles in peer-reviewed journals and has received numerous NCTR and FDA honors and awards for her work, including:

•NCTR “Special Act Award”
•NCTR “Group Recognition Award”
•FDA “Group Recognition Award”

Research Interests

Dr. Wang's primary research focus is on the development and utilization of alternative in vitro testing approaches to provide scientific information and to aid regulatory decisions related to drugs and consumer products. Her current research goals are to develop genotoxicity assays and mutation assays in airway organotypic tissue models and microphysiological systems as a means for providing data for the realistic assessment of human cancer risk. She also is interested in using an in vitro human co-culture system consisting of a placental barrier, that serves as a mediator controlling the molecular transport between mother and fetus, and human embryonic stem cells (hESCs), representing an alternative in vitro model of the developing embryo. The model is being used to study human embryo-fetal developmental toxicity. A third ongoing project uses an advanced human three-dimensional (3D) airway epithelium tissue model and novel aerosol and vapor exposure systems to assess respiratory toxicity under conditions mimicking human inhalation exposure. 

Professional Societies/National and International Groups

Environmental Mutagen and Genomics Society (EMGS)
Member 
2009 – Present

Selected Publications

Dr. Daniel Acosta and In Vitro Toxicology at the U.S. Food and Drug Administration's National Center for Toxicological Research.
Inselman A., Liu F., Wang C., Shi Q., Pang L., Mattes W., White M., Lyn-Cook B., Rosas-Hernandez H., Cuevas E., Lantz S., Imam S., Ali S., Petibone D.M., Shemansky J.M., Xiong R., Wang Y., Tripathi P., Cao X., Heflich R.H., and Slikker W. Jr.
Toxicol In Vitro. 2020, 64:104471. doi: 10.1016/j.tiv.2019.03.003. Epub 2019 Oct 15.

ACB-PCR Quantification of Low-Frequency Hotspot Cancer-Driver Mutations.
Myers M.B., McKim K.L., Wang Y., Banda M., and Parsons B.L.
Methods Mol Biol. 2020, 2102:395-417. doi: 10.1007/978-1-0716-0223-2_23.

Assessing the Respiratory Toxicity of Dihydroxyacetone Using an In Vitro Human Airway Epithelial Tissue Model.
Wang Y., Wu Q., Muskhelishvili L., Davis K., Bryant M., and Cao X.
Toxicol In Vitro. 2019, 59:78-86. doi: 10.1016/j.tiv.2019.04.007. Epub 2019 Apr 5.

Effects of Cellular Differentiation in Human Primary Bronchial Epithelial Cells: Metabolism of 4-(methylnitrosamine)-1-(3-pyridyl)-1-butanone.
Qin Q., Wu Q., Wang Y., Xiong R., Guo L., Fu X., Rosenfeldt H., Bryant M., and Cao X.
Toxicol In Vitro. 2019, 55:185-194. doi: 10.1016/j.tiv.2018.12.006. Epub 2018 Dec 13.

Evaluation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) Mutagenicity Using In Vitro and In Vivo Pig-a Assays.
Mittelstaedt R.A., Dobrovolsky V.N., Revollo J.R., Pearce M.G., Wang Y., Dad A., McKinzie P.B., Rosenfeldt H., Yucesoy B., Yeager R., Hu S.C., Tang Y., Min S., Kang H.K., Yang D.J., Basavarajappa M., and Heflich R.H.
Mutat Res Genet Toxicol Environ Mutagen. 2019, 837:65-72. doi: 10.1016/j.mrgentox.2018.10.007. Epub 2018 Oct 29.

Cigarette Whole Smoke Solutions Disturb Mucin Homeostasis in a Human In Vitro Airway Tissue Model.
Cao X., Wang Y., Xiong R., Muskhelishvili L., Davis K., Richter P.A., and Heflich R.H.
Toxicology. 2018, 409:119-128. doi: 10.1016/j.tox.2018.07.015. Epub 2018 Jul 24.

Establishing a Novel Pig-a Gene Mutation Assay in L5178YTk+/- Mouse Lymphoma Cells.
Wang Y., Revollo J., McKinzie P., Pearce M.G., Dad A., Yucesoy B., Rosenfeldt H., Heflich R.H., and Dobrovolsky V.N.
Environ Mol Mutagen. 2018, 59(1):4-17. doi: 10.1002/em.22152. Epub 2017 Nov 2.

Spectrum of Benzo[a]pyrene-Induced Mutations in the Pig-a Gene of L5178YTk+/- Cells Identified with Next Generation Sequencing.
Revollo J., Wang Y., McKinzie P., Dad A., Pearce M., Heflich R.H., and Dobrovolsky V.N.
Mutat Res. 2017, 824:1-8. doi: 10.1016/j.mrgentox.2017.09.003. Epub 2017 Sep 13.

Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas.
Myers M.B., Banda M., McKim K.L., Wang Y., Powell M.J., and Parsons B.L.
Neoplasia. 2016, 18(4):253-63. doi: 10.1016/j.neo.2016.03.002.

ACB-PCR Quantification of Somatic Oncomutation.
Myers M.B., McKinzie P.B., Wang Y., Meng F., and Parsons B.L.
Methods Mol Biol. 2014, 1105:345-63. doi: 10.1007/978-1-62703-739-6_27.

Temporal Changes in K-ras Mutant Fraction in Lung Tissue of Big Blue B6C3F₁ Mice Exposed to Ethylene Oxide.
Parsons B.L., Manjanatha M.G., Myers M.B., McKim K.L., Shelton S.D., Wang Y., Gollapudi B.B., Moore N.P., Haber L.T., and Moore M.M.
Toxicol Sci. 2013, 136(1):26-38. doi: 10.1093/toxsci/kft190. Epub 2013 Sep 12.

ACB-PCR Measurement of H-ras Codon 61 CAA→CTA Mutation Provides an Early Indication of Aristolochic Acid I Carcinogenic Effect in Tumor Target Tissues.
Wang Y., Arlt V.M., Roufosse C.A., McKim K.L., Myers M.B., Phillips D.H., and Parsons B.L.
Environ Mol Mutagen. 2012, 53(7):495-504. doi: 10.1002/em.21710. Epub 2012 Jun 25.

Hotspot Oncomutations: Implications for Personalized Cancer Treatment.
Myers M.B., Wang Y., McKim K.L., and Parsons B.L.
Expert Rev Mol Diagn. 2012, 12(6):603-20. doi: 10.1586/erm.12.51.

Aristolochic Acid-Induced Carcinogenesis Examined by ACB-PCR Quantification of H-Ras and K-Ras Mutant Fraction.
Wang Y., Meng F., Arlt V.M., Mei N., Chen T., and Parsons B.L.
Mutagenesis. 2011, 26(5):619-28. doi: 10.1093/mutage/ger023. Epub 2011 Jun 3.

p53 Codon 271 CGT to CAT Mutant Fraction Does Not Increase in Nasal Respiratory and Olfactory Epithelia of Rats Exposed to Inhaled Naphthalene.
Meng F., Wang Y., Myers M.B., Wong B.A., Gross E.A., Clewell H.J. 3rd, Dodd D.E., and Parsons B.L.
Mutat Res. 2011, 721(2):199-205. doi: 10.1016/j.mrgentox.2011.02.004. Epub 2011 Feb 13.

Oncomutations as Biomarkers of Cancer Risk.
Parsons B.L., Myers M.B., Meng F., Wang Y., and McKinzie P.B.
Environ Mol Mutagen. 2010, 51(8-9):836-50. doi: 10.1002/em.20600. 

Lab Members

Contact information for all lab members:
(870) 543-7121
NCTRResearch@fda.hhs.gov 

Baiping Ren, Ph.D.
ORISE Fellow

Rui Xiong, Ph.D.
Visiting Scientist

Xuefei Cao, Ph.D.
Research Pharmacologist

Contact Information
Yiying Wang
(870)543-7121
Expertise
Expertise
Approach
Domain
Carcinogenicity
Technology & Discipline
Toxicology
Back to Top